1-(2-Chloropyrimidin-4-yl)piperidine-4-carboxylic acid

Catalog No.: 
ACKBLY514
CAS No.: 
1208087-83-5
Molecular Formula: 
C10H12ClN3O2
Molecular Weight: 
241.68
1-(2-Chloropyrimidin-4-yl)piperidine-4-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%
5g95%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(2-Chloropyrimidin-4-yl)piperidine-4-carboxylic acid
IUPAC Name1-(2-chloropyrimidin-4-yl)piperidine-4-carboxylic acid
MDL No.MFCD11040198
Molecular FormulaC10H12ClN3O2
Molecular Weight241.68
SMILESO=C(C1CCN(C2=NC(Cl)=NC=C2)CC1)O
InChI KeyFHKSKATXLAGIAS-UHFFFAOYSA-N
Synonym1-(2-chloropyrimidin-4-yl)piperidine-4-carboxylic acid | 1208087-83-5 | MFCD11040198 | SCHEMBL14810701 | DTXSID00672069 | BBL031759 | STL161674 | AKOS005761214 | DS-0954 | SB43242 | AM20080546 | CS-0155580 | EN300-6764160 | A892042 | 1-(2-chloropyrimidin-4-yl)piperidine-4-carboxylic
CAS No.1208087-83-5
PubChem CID45789847

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACKBLY514 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHWTV965 route compound structure diagram
    ACHWTV965889126-33-4In Stock
  2. Then
  3. ACKBLY514 route product structure diagram
    ACKBLY5141208087-83-5In Stock
Inquiry

2. ACKBLY514 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACKBLY514 route product structure diagram
    ACKBLY5141208087-83-5In Stock
Inquiry

3. ACKBLY514 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACKBLY514 route product structure diagram
    ACKBLY5141208087-83-5In Stock
Inquiry

Comments (0)